Por: RTTNews Health November 21, 2022
Merck () and Imago BioSciences, Inc. () have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for $36.00 per share in cash for an approximate total equity value of $1.35 billion. The acquisition is expected to close in the first quarter of 2023.Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing small molecule product candidates that target lysine-specific... + full article
ABC News USA Business November 22, 2022
NEW YORK -- Stocks that traded heavily or had substantial price changes Monday:Carvana Co., down $1.01 to $7.05.The used-vehicle chain is cutting 1,500 jobs, or 8% of its workforce.The Walt Disney Co., up $5.78 to $97.58.Bob Iger is returning as CEO of the entertainment company... + más
98% Below Its High, Morgan Stanley Says Carvana Stock Could Fall To $1 | Forbes
Merck To Acquire Imago BioSciences | RTTNews
CNBC USA Tech November 03, 2022
Shara Ticku and David Heller, co-founders of C16 Biosciences.Photo courtesy C16 Biosciences.In July 2013, traveled to Singapore on a work trip for Goldman Sachs. The investment bank made her bring N95 masks to protect her from the terrible air quality at the time.I land in... + más
Ancient Microbes Could Still Be Living on Mars | Time
Nick Gates snaps to Daniel Jones at Wednesday’s practice: ‘I’m happy for him’ | New York Daily News
MarketWatch USA Business October 27, 2022
“Three transactions shows deals can get done,” Litchfield says. “Where science and value align, we will act.” Merck shares were up 1.6% on Thursday, trading at a flat $100 per share, after the company that beat Wall Street expectations. Merck’s sales were $15 billion... + más
Moderna and Merck will jointly develop a cancer vaccine for high-risk melanoma patients | CNBC
Drugmaker Merck tops 3Q forecasts as Keytruda sales jump 20% | Associated Press
Associated Press USA Health October 27, 2022
Merck turned in a better-than-expected third quarter and raised its 2022 forecast as the drugmaker’s top seller brought in over a third of its revenue. Sales of the cancer fighter Keytruda grew 20% to more than $5.4 billion in the quarter and would have jumped 26% without the... + más
Merck Says Health Canada Granted Approval For KEYTRUDA To Treat Renal Cell Carcinoma | RTTNews
The Boston Globe USA Business October 13, 2022
COVID-19 vaccine maker Moderna’s stock rose the most in two months after Merck & Co. said it would exercise an option to work in partnership with the biotech on a messenger RNA cancer vaccine.Moderna will receive $250 million from Merck in exchange for joint development and... + más
Moderna sues Pfizer over patents behind COVID-19 vaccine | The Advocate
CNBC USA Health October 12, 2022
Pipettes are seen at the Moderna Therapeutics Inc. lab in Cambridge, Massachusetts, U.S., on Tuesday, Nov. 14, 2017. Moderna this week started testingAdam Glanzman Bloomberg Getty Images and will jointly develop and sell a cancer vaccine that is personalized for individual... + más
Moderna surges as Merck ramps up collaboration on cancer vaccine | The Boston Globe
The Advocate USA Business October 04, 2022
A major international pharmaceutical company has spent more than $1 million to convert a North Baton Rouge veterinary medicine manufacturing facility into a plant that makes ear tags for cattle.Merck Animal Health said 33 people work in the plant at 2667 W. Dual St., roughly the... + más
How to change AirPods Pro ear tips and run the custom fit test | 9to5Mac
'This river is something else': American Queen brings tourists to Baton Rouge on the river | The Advocate
About iurex | Privacy Policy | Disclaimer |